A tumor necrosis factor mimetic peptide activates a murine macrophage cell line to inhibit mycobacterial growth in a nitric oxide-dependent fashion

Infection and Immunity

Volumn 66, Issue 5, 1998, Pages 2122-2127

  Britton, W J ^a,b   Meadows, N ^a   Rathjen, D A ^c,d   Roach, D R ^a   Briscoe, H ^a,b  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c TEVA PHARMACEUTICALS   (Israel)

^d WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; BACTERIAL GROWTH; CELLULAR IMMUNITY; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MONONUCLEAR CELL; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0031948383     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.5.2122-2127.1998     Document Type: Article

References (40)

1. Adams, L. B., C. M. Mason, J. K. Kolls, D. Scollard, J. L. Krahenbuhl, and S. Nelson. 1995. Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus. J. Infect. Dis. 171:400-405.
2. Antoni, G., R. Presentini, F. Perin, A. Tagliaube, P. Ghiara, S. Censini, G. Volpini, L. Villa, and D. Boraschi. 1985. A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity. J. Immunol. 137:3201-3209.
3. Ashkenazi, A., S. A. Marsters, D. J. Capon, S. M. Chamow, I. S. Figari, D. Pennica, D. Goedell, M. A. Palladino, and D. H. Smith. 1991. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc. Natl. Acad. Sci. USA 88:10535-10539.
4. Atherton, E., H. Fox, D. Harkiss, C. J. Logan, R. C. Sheppard, and B. J. Williams. 1978. A mild procedure for solid phase peptide synthesis: use of fluorenylmerhoxy carbonyl amino acids. J. Chem. Soc. Chem. Commun. 13: 537-543.
5. Banner, D. W., A. D'Arcy, W. Janes, R. Gentz, H. J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73:431-445.
6. Bazzoni, F., and B. Beutler. 1996. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334:1717-1725.
7. Boraschi, D. L., P. Bossu, P. Ruggerio, A. Tagliabue, R. Bertini, G. Macchia, C. Gasbarro, L. Pellegrini, G. Melillo, E. Ulisse, U. Visconti, C. Bizzari, E. DelGrosso, A. R. Mackay, G. Frascotti, F. Frigerio, R. Grifantini, and G. Grandi. 1995. Mapping of the receptor binding sites on IL-1β by reconstruction of the IL-1Ra-like domains. J. Immunol. 155:4719-4718.
8. Britton, W., L. Hellqvist, A. Basten, and R. L. Raison. 1985. Mycobacterium leprae antigens involved in human immune responses. I. Identification of four antigens by monoclonal antibodies. J. Immunol. 135:4171-4177.
9. Butler, D. M., B. Scallon, A. Meager, M. Kissonerghis, A. Corcoran, Y. Chernajovsky, M. Feldmann, J. Ghrayeb, and F. Brennan. 1994. TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells. Cytokine 6:616-623.
10. Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B. R. Bloom. 1995. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63:736-740.
11. Chan, J., Y. Xing, R. S. Magliozzo, and B. R. Bloom. 1992. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:1111-1122.
12. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in interferon-γ gene disrupted mice. J. Exp. Med. 178:2243-2247.
13. Denis, M. 1991. Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. J. Leukocyte Biol. 50:495-501.
14. Denis, M. 1991. Killing of Mycobacterium tuberculosis within human monocytes: activation by cytokines and calcitriol. Clin. Exp. Immunol. 84:200-206.
15. Denis, M. 1991. Tumour necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J. Leukocyte Biol. 49:380-387.
16. Desiderio, J. V., P. A. Kiener, P.-F. Lin, and G. A. Warr. 1989. Protection of mice against Listeria monocytogenes infection by recombinant tumor necrosis factor alpha. Infect. Immun. 57:1615-1617.
17. Eck, M. J., M. Ultsch, E. Rinderknecht, A. M. de Vos, and S. R. Sprang. 1992. The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J. Biol. Chem. 267:2119-2122.
18. Flesch, I. E. A., and S. H. E. Kaufmann. 1990. Activation of tuberculostatic macrophage functions by gamma Interferon, interleukin-4, and tumor necrosis factor. Infect. Immun. 58:2675-2677.
19. Flesch, I. E. A., and S. H. E. Kaufmann. 1990. Stimulation of antibacterial macrophage activities by B-cell stimulatory factor 2 (interleukin-6). Infect. Immun. 58:269-271.
20. Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential role for Interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249-2254.
21. Flynn, J. L., M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, R. Schreiber, T. W. Mak, and B. R. Bloom. 1995. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572.
22. 15N]nitrate in biological fluids. Anal. Biochem. 126:131-138.
23. Hakim, A., S. Levy, and R. Levy. 1996. A nine-amino acid peptide from IL-1β augments antitumor immune responses induced by protein and DNA vaccines. J. Immunol. 157:5503-5511.
24. Kaufmann, S. H. E. 1993. Immunity to intracellular mycobacteria. Annu. Rev. Immunol. 11:129-163.
25. Kindler, V., A. P. Sappino, G. E. Grau, P.-F. Piguet, and P. Vassalli. 1989. The inducing role of tumour necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731-740.
26. Korner, H., A. L. Goodsall, F. Lemckert, B. J. Scallon, J. Ghrayer, A. L. Ford, and J. D. Sedgwick. 1995. Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalitis. Proc. Natl. Acad. Sci. USA 92:11066-11070.
27. Kumaratilake, L. M., D. A. Rathjen, P. Mack, F. Widmer, V. Prasertsiriroj, and A. Ferrante. 1995. A synthetic tumour necrosis factor-α agonist peptide enhances human polymorphonuclear leukocyte-mediated killing of Plasmodium falciparum in vitro and suppresses Plasmodium chabaudi infection in mice. J. Clin. Invest. 95:2315-2323.
28. Langermans, J. A. M., M. E. B. van der Hulst, P. H. Nibbering, and R. van Furth. 1992. Endogenous tumor necrosis factor alpha is required for enhanced antimicrobial activity against Toxoplasma gondii and Listeria monocytogenes in recombinant gamma interferon-treated mice. Infect. Immun. 60: 5107-5112.
29. MacMicking, J. D., C. F. Nathan, G. Hom, N. Chartrain, D. S. Fletcher, M. Trumbauer, K. Stevens, Q.-W. Xie, K. Sokol, N. Hutchinson, H. Chen, and J. S. Mudgett. 1995. Altered response to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81:641-680.
30. MacMicking, J. D., R. J. North, R. LaCourse, J. S. Mudgett, S. K. Shah, and C. F. Nathan. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. USA 94:5243-5248.
31. Pfeffer, K., T. Matsuyama, T. M. Kündig, A. Wakeman, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Kronke, and T. W. Mak. 1993. Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467.
32. Rathjen, D., K. Cowan, L. Furphy, and R. Aston. 1991. Antigenic structure of human tumour necrosis factor recognition hy distinct regions of TNF by different tumour cell receptors. Mol. Immunol. 28:79-86.
33. 32a.Rathjen, D. A. Unpublished data.
34. Rathjen, D. A., A. Ferrante, and R. Aston. 1993. Differential effects of small tumour necrosis factor α peptides on tumour cytotoxicity, neutrophil activation and endothelial cell procoagulant. Immunology 80:293-299.
35. Rhoades, E. R., and Orme, I. M. 1997. Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect. Immun. 65:1189-1195.
36. 34a.Roach, D. R. Unpublished data.
37. Sarno, E. N., G. E. Grau, L. M. M. Vieira, and J. A. Nery. 1991. Serum levels of tumour necrosis factor-α and interleukin-1β during leprosy reactional states. Clin. Exp. Immunol. 84:103-108.
38. Tuerlinck, D., C. Vermylen, B. Brichard, J. Ninane, and G. Cornu. 1997. Disseminated Mycobacterium avium infection in a child with decreased tumour necrosis factor production. Eur. J. Pediatr. 156:204-206.
39. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411-451.
40. Wrighton, N. C., F. X. Farrell, R. Chang, A. K. Kashyap, F. P. Barbone, L. S. Mulcahy, D. L. Johnson, R. W. Barrett, L. K. Jolliffe, and W. J. Dower. 1996. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273:458-463.